Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Hepatoblastoma 1Adrenocortical Carcinoma 1

Interventions

Cyclophosphamide 6Thiotepa 5Granulocyte Colony-Stimulating Factor 4Filgrastim 4Etoposide 4Cisplatin 4Busulfan 4tislelizumab 3Melphalan 3Carboplatin 3tazemetostat 2regorafenib 2pembrolizumab 2belinostat 2Topotecan 2Temozolomide 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Mesna 2Ifosfamide 2Doxorubicin 2spartalizumab 1sodium thiosulfate 1sargramostim 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1entinostat 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × cixutumumab × Other solid neoplasm × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡